

# Alexandre Persu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4314724/publications.pdf>

Version: 2024-02-01

120  
papers

4,630  
citations

156536

32  
h-index

129628

63  
g-index

123  
all docs

123  
docs citations

123  
times ranked

5228  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.4	30
2	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. <i>Cardiovascular Research</i> , 2022, 118, 65-83.	1.8	14
3	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 31-42.	1.4	14
4	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. <i>Hypertension</i> , 2022, 79, 12-23.	1.3	51
5	Increased Collagen Turnover Is a Feature of Fibromuscular Dysplasia and Associated With Hypertrophic Radial Remodeling: A Pilot, Urine Proteomic Study. <i>Hypertension</i> , 2022, 79, 93-103.	1.3	4
6	Prevalence and Disease Spectrum of Extracoronary Arterial Abnormalities in Spontaneous Coronary Artery Dissection. <i>JAMA Cardiology</i> , 2022, 7, 159.	3.0	18
7	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. <i>EBioMedicine</i> , 2022, 77, 103893.	2.7	48
8	Association between post-traumatic stress disorder and hypertension in Congolese exposed to violence: a case-control study. <i>Journal of Hypertension</i> , 2022, 40, 685-691.	0.3	6
9	Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation. <i>Blood Pressure</i> , 2022, 31, 109-117.	0.7	2
10	Hypertension in older patients: a STEP forward?. <i>Blood Pressure</i> , 2022, 31, 118-120.	0.7	2
11	Mild chronic hypertension in pregnancy: to treat or wait?. <i>Blood Pressure</i> , 2022, 31, 121-124.	0.7	1
12	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI) clinical phenotypes and their predictors based on a cohort of 1000 patients. <i>Cardiovascular Research</i> , 2021, 117, 950-959.	1.8	33
13	<i>PTGIR</i> , a susceptibility gene for fibromuscular dysplasia?. <i>Cardiovascular Research</i> , 2021, 117, 990-992.	1.8	1
14	Intrarenal hemodynamics and kidney function in pheochromocytoma and paraganglioma before and after surgical treatment. <i>Blood Pressure</i> , 2021, 30, 1-8.	0.7	0
15	Starting Antihypertensive Drug Treatment With Combination Therapy. <i>Hypertension</i> , 2021, 77, 800-805.	1.3	9
16	2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. <i>Journal of Hypertension</i> , 2021, 39, 1293-1302.	0.3	349
17	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1326-1346.	0.4	18
18	Hypertension in kidney transplantation: a consensus statement of the "hypertension and the kidney" working group of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1513-1521.	0.3	16

#	ARTICLE	IF	CITATIONS
19	Kidney donors with fibromuscular dysplasia, is it time to open the doors?. Nephrology Dialysis Transplantation, 2021, 36, 1365-1368.	0.4	1
20	Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia. Journal of the American Heart Association, 2021, 10, e018311.	1.6	7
21	Combination of acute hypertensive striatocapsular hemorrhage and mirror previous asymptomatic slit-like hemorrhage in a young patient: a new radiological clue for cerebral small vessel disease?. Acta Neurologica Belgica, 2021, 121, 1371-1373.	0.5	1
22	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.3	197
23	European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 2021, 39, 1733-1741.	0.3	88
24	Baseline Brain-to-Pelvis Imaging Predicts Subsequent Arterial Complications in Patients With Renal Artery Dissection. Hypertension, 2021, 78, 62-64.	1.3	1
25	Fibromuscular dysplasia: its various phenotypes in everyday practice in 2021. Kardiologia Polska, 2021, 79, 733-744.	0.3	10
26	Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Pressure, 2021, 30, 282-290.	0.7	13
27	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. American Heart Journal, 2021, 239, 90-99.	1.2	16
28	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e010075.	1.4	8
29	Blood pressure lowering with alcohol-mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. Catheterization and Cardiovascular Interventions, 2021, 98, E832-E838.	0.7	0
30	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	1.3	12
31	Influence of secretory phenotype and preoperative preparation on surgical outcome in pheochromocytoma. Endocrine Connections, 2021, 10, 92-101.	0.8	5
32	Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. Journal of Hypertension, 2021, 39, 1077-1089.	0.3	44
33	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. Nature Communications, 2021, 12, 6031.	5.8	34
34	Adherence to antihypertensive drug treatment in kidney transplant recipients. Blood Pressure, 2021, 30, 411-415.	0.7	2
35	Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2020, 35, 878-887.	0.4	32
36	Multi-omics applied to fibromuscular dysplasia: first steps on a new research avenue. Cardiovascular Research, 2020, 116, 4-5.	1.8	4

#	ARTICLE	IF	CITATIONS
37	Benefit of serum drug monitoring complementing urine analysis to assess adherence to antihypertensive drugs in first-line therapy. PLoS ONE, 2020, 15, e0237383.	1.1	13
38	Renal Denervation in Hypertensive Patients. Hypertension, 2020, 76, 1084-1086.	1.3	4
39	Enrichment of Rare Variants in Loey's "Dietz Syndrome Genes in Spontaneous Coronary Artery Dissection but Not in Severe Fibromuscular Dysplasia. Circulation, 2020, 142, 1021-1024.	1.6	30
40	Increased Blood Pressure Variability May Herald Cognitive Decline and Dementia. Hypertension, 2020, 76, 1076-1078.	1.3	2
41	Indirect implications of COVID-19 prevention strategies on non-communicable diseases. BMC Medicine, 2020, 18, 256.	2.3	34
42	Genetic Study of <i>PHACTR1</i> and Fibromuscular Dysplasia, Meta-Analysis and Effects on Clinical Features of Patients. Hypertension, 2020, 76, e4-e7.	1.3	9
43	Assessment of adherence to diuretics and $\beta$ -blockers by serum drug monitoring in comparison to urine analysis. Blood Pressure, 2020, 29, 291-298.	0.7	5
44	Home blood pressure monitoring and e-Health: investigation of patients' experience with the Hy-Result system. Blood Pressure Monitoring, 2020, 25, 155-161.	0.4	9
45	Brain-to-Pelvis Imaging Substantially Impacts Management of Patients With Fibromuscular Dysplasia. Hypertension, 2020, 75, 945-947.	1.3	0
46	Pregnancy-Related Complications in Patients With Fibromuscular Dysplasia. Hypertension, 2020, 76, 545-553.	1.3	10
47	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. JACC: Cardiovascular Interventions, 2020, 13, 471-484.	1.1	73
48	Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	1.8	282
49	Dissecting visceral fibromuscular dysplasia reveals a new vascular phenotype of the disease: a report from the ARCADIA-POL study. Journal of Hypertension, 2020, 38, 737-744.	0.3	7
50	Fibromuscular Dysplasia: From a Rare Cause of Renovascular Hypertension to a More Frequent Systemic Arterial Disease. Updates in Hypertension and Cardiovascular Protection, 2020, , 33-57.	0.1	0
51	ESC Council on hypertension position document on the management of hypertensive emergencies. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 37-46.	1.4	155
52	Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views. Nephrology Dialysis Transplantation, 2019, 34, 1612-1615.	0.4	6
53	Predictors of blood pressure control in patients with resistant hypertension after intensive management in two expert centres: the Brussels-Torino experience. Blood Pressure, 2019, 28, 336-344.	0.7	9
54	Paroxysmal Hypertension Associated With Urination. Hypertension, 2019, 74, 1068-1074.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Prevalence and characteristics of renal artery fibromuscular dysplasia in hypertensive women below 50 years old. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13166.	1.7	7
56	Arterial Tortuosity. <i>Hypertension</i> , 2019, 73, 951-960.	1.3	110
57	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
58	Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPIRED pilot study. <i>Blood Pressure</i> , 2019, 28, 168-172.	0.7	11
59	Future of Renal Sympathetic Denervation in the Treatment of Hypertension. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1643-1645.	1.2	7
60	Spontaneous coronary artery dissections and fibromuscular dysplasia: Current insights on pathophysiology, sex and gender. <i>International Journal of Cardiology</i> , 2019, 286, 220-225.	0.8	17
61	First International Consensus on the diagnosis and management of fibromuscular dysplasia. <i>Vascular Medicine</i> , 2019, 24, 164-189.	0.8	232
62	Cervical artery dissection: fibromuscular dysplasia versus vascular Ehlers-Danlos syndrome. <i>Blood Pressure</i> , 2019, 28, 139-143.	0.7	5
63	Unifocal and Multifocal Fibromuscular Dysplasia. <i>Hypertension</i> , 2019, 73, 7-12.	1.3	5
64	Fibromuscular Dysplasia and Its Neurologic Manifestations. <i>JAMA Neurology</i> , 2019, 76, 217.	4.5	50
65	First international consensus on the diagnosis and management of fibromuscular dysplasia. <i>Journal of Hypertension</i> , 2019, 37, 229-252.	0.3	80
66	Long-term cardiovascular outcome after renal revascularization. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 735-737.	0.3	0
67	European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. <i>European Heart Journal</i> , 2018, 39, 3353-3368.	1.0	421
68	Management of a Pregnant Woman With Fibromuscular Dysplasia. <i>Hypertension</i> , 2018, 71, 540-547.	1.3	11
69	Renal infarction management. <i>Journal of Hypertension</i> , 2018, 36, 490-492.	0.3	7
70	Hypertension, a Posttraumatic Stress Disorder?. <i>Hypertension</i> , 2018, 71, 811-812.	1.3	8
71	Home blood pressure measurement and digital health. <i>Journal of Hypertension</i> , 2018, 36, 2125-2131.	0.3	15
72	Visceral Fibromuscular Dysplasia: From asymptomatic disorder to emergency. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13023.	1.7	5

#	ARTICLE	IF	CITATIONS
73	Focus on increased serum angiotensin-converting enzyme level: From granulomatous diseases to genetic mutations. <i>Clinical Biochemistry</i> , 2018, 59, 1-8.	0.8	27
74	Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. <i>Blood Pressure</i> , 2018, 27, 358-367.	0.7	20
75	Genomics of Fibromuscular Dysplasia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1526.	1.8	35
76	Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?. <i>Current Hypertension Reports</i> , 2017, 19, 5.	1.5	21
77	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association "European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 620-640.	0.4	133
78	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. <i>Blood Pressure</i> , 2017, 26, 321-331.	0.7	20
79	Hypertension in dialysis patients. <i>Journal of Hypertension</i> , 2017, 35, 657-676.	0.3	56
80	Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. <i>Blood Pressure</i> , 2017, 26, 195-203.	0.7	31
81	KIF1B and NF1 are the most frequently mutated genes in paraganglioma and pheochromocytoma tumors. <i>Endocrine-Related Cancer</i> , 2017, 24, L57-L61.	1.6	16
82	High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia. <i>Hypertension</i> , 2017, 70, 652-658.	1.3	115
83	STK39 and WNK1 Are Potential Hypertension Susceptibility Genes in the BELHYPCGEN Cohort. <i>Medicine (United States)</i> , 2016, 95, e2968.	0.4	14
84	Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation. <i>Hypertension</i> , 2016, 67, 1211-1217.	1.3	40
85	Renal Nerve Stimulation "Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation. <i>Hypertension</i> , 2016, 68, 707-714.	1.3	77
86	Revisiting Fibromuscular Dysplasia. <i>Hypertension</i> , 2016, 68, 832-839.	1.3	55
87	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. <i>Hypertension</i> , 2016, 68, 297-306.	1.3	147
88	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. <i>Current Hypertension Reports</i> , 2016, 18, 6.	1.5	32
89	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	2.9	176
90	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 48-56.	1.4	7

#	ARTICLE	IF	CITATIONS
91	Renal denervation in treatment-resistant hypertension: a reappraisal. <i>Current Opinion in Pharmacology</i> , 2015, 21, 48-52.	1.7	11
92	Design of renal denervation studies not confounded by antihypertensive drugs. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 337-340.	2.3	5
93	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. <i>Frontiers in Physiology</i> , 2015, 6, 9.	1.3	12
94	The Setback of Renal Denervation Should Not Backfire on "Sympathetic Overactivity in Hypertension". <i>Journal of the American College of Cardiology</i> , 2015, 65, 1322-1323.	1.2	5
95	Eligibility for Renal Denervation. <i>Hypertension</i> , 2014, 63, 1319-1325.	1.3	61
96	Renal sympathetic denervation in the aftermath of Symplicity HTN-3. <i>Blood Pressure</i> , 2014, 23, 256-261.	0.7	6
97	Use of ambulatory blood pressure measurement in the definition of resistant hypertension: a review of the evidence. <i>Hypertension Research</i> , 2014, 37, 967-972.	1.5	30
98	Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPIRED) trial. <i>Blood Pressure</i> , 2014, 23, 138-146.	0.7	15
99	Con: Renal denervation for all resistant hypertensive patients: the Emperor's new clothes. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1116-1119.	0.4	2
100	Hyperresponders vs. nonresponder patients after renal denervation. <i>Journal of Hypertension</i> , 2014, 32, 2422-2427.	0.3	37
101	European consensus on the diagnosis and management of fibromuscular dysplasia. <i>Journal of Hypertension</i> , 2014, 32, 1367-1378.	0.3	154
102	Letter by Jin et al Regarding Article, "Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension". <i>Circulation</i> , 2014, 129, e499.	1.6	4
103	Denervation of Native Kidneys in a Renal Transplant Recipient: One Swallow Does Not Make a Spring. <i>American Journal of Hypertension</i> , 2014, 27, 897-898.	1.0	1
104	Systematic Review of Health Outcomes in Relation to Salt Intake Highlights the Widening Divide Between Guidelines and the Evidence. <i>American Journal of Hypertension</i> , 2014, 27, 1138-1142.	1.0	8
105	Renal Denervation after Symplicity HTN-3: An Update. <i>Current Hypertension Reports</i> , 2014, 16, 460.	1.5	29
106	Hyper-responders vs. non-responder patients after renal denervation: do they differ?. <i>Journal of the American Society of Hypertension</i> , 2014, 8, e117.	2.3	1
107	Renal artery stenosis following renal denervation. <i>Journal of Hypertension</i> , 2014, 32, 2101-2105.	0.3	26
108	Diagnosis and management of fibromuscular dysplasia. <i>Journal of Hypertension</i> , 2014, 32, 2098-2099.	0.3	0

#	ARTICLE	IF	CITATIONS
109	SYMPPLICITY HTN-3 results to be announced: a mystery or a story foretold?. Journal of Biomedical Research, 2014, 28, 73.	0.7	1
110	Residual Effect of Renal Denervation in Patients With Truly Resistant Hypertension. Hypertension, 2013, 62, 450-452.	1.3	16
111	Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence. Expert Review of Cardiovascular Therapy, 2013, 11, 739-749.	0.6	25
112	A Novel Splice-Site Mutation in Angiotensin I-Converting Enzyme (ACE) Gene, c.3691+1G>A (IVS25+1G>A), Causes a Dramatic Increase in Circulating ACE through Deletion of the Transmembrane Anchor. PLoS ONE, 2013, 8, e59537.	1.1	22
113	Renal Denervation. Hypertension, 2012, 60, 596-606.	1.3	90
114	Diagnosis and management of fibromuscular dysplasia: an expert consensus. European Journal of Clinical Investigation, 2012, 42, 338-347.	1.7	92
115	Physician attitudes to blood pressure control. Journal of Hypertension, 2011, 29, 1633-1640.	0.3	37
116	Rare presentation of familial paraganglioma without evidence of mutation in the SDH, RET and VHL genes: towards further genetic heterogeneity. Journal of Hypertension, 2009, 27, 76-82.	0.3	2
117	High prevalence of SDHB mutations in head and neck paraganglioma in Belgium. Journal of Hypertension, 2008, 26, 1395-1401.	0.3	16
118	Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: sib-pair analysis and haplotype study. Journal of Hypertension, 2005, 23, 759-765.	0.3	16
119	Transepithelial chloride secretion and cystogenesis in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2000, 15, 747-750.	0.4	11
120	CF Gene and Cystic Fibrosis Transmembrane Conductance Regulator Expression in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2000, 11, 2285-2296.	3.0	41